The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

Dvora Sredni-Kenigsbuch; Michael Shohat; Batia Shohat; Dan Ben-Amitai; Chi-Chao Chan; Michael David

doi:10.1016/j.jdermsci.2007.12.007

The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

J Dermatol Sci. 2008 Jun;50(3):232-5. doi: 10.1016/j.jdermsci.2007.12.007. Epub 2008 Jan 31.

Authors

Dvora Sredni-Kenigsbuch, Michael Shohat, Batia Shohat, Dan Ben-Amitai, Chi-Chao Chan, Michael David

PMID: 18242062
DOI: 10.1016/j.jdermsci.2007.12.007

Abstract

The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNgamma and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

Publication types

Letter

MeSH terms

Adjuvants, Immunologic / pharmacology*
Child
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / immunology*
Ethylenes / pharmacology*
Humans
In Vitro Techniques
Interleukin-10 / metabolism*
p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

Adjuvants, Immunologic
Ethylenes
IL10 protein, human
Interleukin-10
ammonium trichloro(dioxoethylene-O,O'-)tellurate
p38 Mitogen-Activated Protein Kinases